Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. develops prescription transdermal pharmaceutical products and abuse-deterrent patch technology. Company news centers on AVERSA, its transdermal platform that incorporates aversive agents into patches intended to deter abuse, diversion, misuse and accidental exposure for drugs with abuse potential, including opioids and stimulants.
Recurring updates cover the AVERSA Fentanyl program, regulatory and intellectual-property steps, product naming and labeling work, and development relationships tied to transdermal fentanyl. Other company developments include sports tape and kinesiology products, mosquito repellent patches, distribution arrangements, subsidiary matters, shareholder meeting topics, and capital-structure updates affecting Nutriband's Nasdaq-listed common stock and warrants.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will participate in Benzinga ALL ACCESS on February 4, 2022, featuring CEO Gareth Sheridan at 10AM ET. The event can be streamed live here. Nutriband specializes in developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing their AVERSA™ technology. This technology aims to prevent the misuse and accidental exposure of drugs. For more details, visit www.nutriband.com.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a notification from the USPTO confirming the issuance of a patent for its AVERSA™ transdermal abuse deterrent technology.
This technology aims to prevent the misuse of drugs by incorporating aversive agents into transdermal patches. The patent secures the company’s lead product, AVERSA™ Fentanyl, which could become the first fentanyl patch with abuse deterrent properties. Nutriband is also expanding its pipeline to include other drugs, enhancing safety against misuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has expanded its product development pipeline for its AVERSA™ abuse deterrent transdermal technology. The lead product, AVERSA Fentanyl, could tap into a market worth $80 - $200 million. Additionally, AVERSA buprenorphine and AVERSA methylphenidate are now part of the pipeline, targeting existing products with abuse potential. The technology aims to deter misuse while ensuring drug availability. A feasibility agreement with Kindeva Drug Delivery has initiated the development of AVERSA Fentanyl, enhancing Nutriband's strategic focus on abuse deterrent formulations.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a feasibility agreement with Kindeva Drug Delivery to develop its lead product, AVERSA™ Fentanyl, utilizing AVERSA™ abuse deterrent technology. This partnership aims to adapt Kindeva's transdermal manufacturing process for AVERSA technology. The technology includes aversive agents to prevent drug abuse and is supported by a robust patent portfolio. CEO Gareth Sheridan expressed optimism about improving safety for fentanyl users while maintaining accessibility for patients in need.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has completed a market assessment for its lead product, Aversa™ Fentanyl, an innovative abuse-deterrent fentanyl transdermal system. Conducted by Health Advances, the analysis suggests that Aversa has the potential for peak annual US sales ranging from $80-200 million within five years post-launch. The company aims to follow a 505(b)(2) NDA regulatory path towards FDA approval, targeting a safer alternative amidst rising concerns over opioid abuse. This product may redefine the transdermal fentanyl market by introducing crucial safety features.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the Korean Intellectual Property Office has issued a full patent for its Abuse and Misuse Deterrent Transdermal System, related to its lead technology AVERSA. This technology aims to prevent opioid abuse through taste aversion methods. A prior notice of allowance was issued in December 2020. Nutriband focuses on developing transdermal pharmaceutical products, with AVERSA designed to mitigate risks associated with abuse, misuse, and accidental exposure.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the company had 7,773,962 shares outstanding. This buyback aims to enhance shareholder value and signal confidence in the company's future. Nutriband is focused on developing transdermal pharmaceutical products, particularly an abuse-deterrent fentanyl patch using its AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced plans to offer contract manufacturing services for liquid-based topical products, following its recent cGMP certification. This certification relates to Pharmaceutical OTC GMP, 21 CFR Part 211/210, enhancing the company's manufacturing capabilities. CEO Gareth Sheridan stated that expanding these capabilities aligns with the company's revenue growth strategy for 2022. Nutriband is primarily focused on developing transdermal pharmaceutical products, including its abuse deterrent fentanyl patch utilizing AVERSA technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its manufacturing subsidiary, Active Intelligence, has successfully received cGMP certification after a thorough audit. This certification is vital for expanding their contract manufacturing services on a national and international scale. CEO Gareth Sheridan highlighted that this achievement will enable the company to enhance its product offerings and explore new market opportunities, which are crucial for the company’s growth strategy.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its CEO Gareth Sheridan and President Serguei Melnik, accompanied by board members and senior management, will ring the NASDAQ Opening Bell on December 3, 2021, at 9:30 a.m. EST. Sheridan expressed gratitude for the teamwork and support that enabled the company’s journey so far. Nutriband focuses on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA™ technology. A live stream of the ceremony will be available online.